Resolution of the Expert Council “New approaches to the treatment of axial spondyloarthritis”-Reference-Cited by-同舟云学术

Resolution of the Expert Council “New approaches to the treatment of axial spondyloarthritis”

Published:2024-06-16 Issue:3 Volume:18 Page:134-139
ISSN:2310-158X
Container-title:Modern Rheumatology Journal
language:
Short-container-title:Sovremennaâ revmatologiâ

Author:

Lila A. M.¹^ORCID,Mazurov V. I.²^ORCID,Nasonov E. L.³^ORCID,Lukyanov S. A.⁴^ORCID,Dubinina T. V.⁵^ORCID,Gaidukova I. Z.⁶^ORCID,Klimenko A. A.⁴^ORCID,Lapshina S. A.⁷^ORCID,Lukina G. V.⁸^ORCID,Korolev M. A.⁹^ORCID,Dreval R. O.¹⁰^ORCID,Pchelnikova P. I.¹¹,Shatalova N. V.¹²

Affiliation:

1. V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

2. North-Western State Medical University named after I.I. Mechnikov, Ministry of Health of Russia

3. V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

4. Pirogov Russian National Research Medical University, Ministry of Health of Russia

5. V.A. Nasonova Research Institute of Rheumatology

6. North-Western State Medical University named after I.I. Mechnikov, Ministry of Health of Russia; Clinical Rheumatological Hospital № 25

7. Kazan State Medical University, Ministry of Health of Russia

8. V.A. Nasonova Research Institute of Rheumatology; A.S. Loginov Moscow Clinical Scientific and Practical Center

9. Institute of Clinical and Experimental Lymphology – branch of the Institute of Cytology and Genetics SB RAS

10. Center for Social Economics

11. Russian Union Of Patients Public Societies; All-Russian Non-profit Organization of disabled people “Russian Rheumatological Association “Nadezhda”

12. Interregional public charity organization for people with disabilities “Mutual Aid Society for Bekhterev’s Disease”

Abstract

On 30 May, 2024, an expert meeting was held to update the approaches for the treatment of axial spondyloarthritis (axSpA). A new approach to the treatment of axSpA was considered, which consists of depleting autoreactive TRBV9+ T- lymphocytes by introducing a monoclonal antibody – the drug seniprutug. The value of the drug seniprutug in the treatment of the disease was discussed and key aspects for the incorporation of the drug seniprutug into real-world clinical rheumatological practice were agreed.

Publisher

IMA Press, LLC

Reference8 articles.

1. Britanova OV, Lupyr KR, Staroverov DB, et al. Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis. Nat Med. 2023 Nov;29(11):2731-2736. doi: 10.1038/s41591-023-02613-z. Epub 2023 Oct 23.

2. Gaidukova IZ, Mazurov VI. The pathogenesis of axial spondyloarthritis as the basis of treatment — realities and prospects. Russkii meditsinskii zhurnal. 2023;(7):6-14. (In Russ.)

3. Decision of the Council of the Eurasian Economic Commission dated 03. 11. 2016 № 78 (as amended on 10/20/2023) "On the Rules for registration and examination of medicines for medical use" https://docs.eaeunion.org/docs/ru-ru/01411969/cncd_21112016_78

4. General characteristics of the medicinal product (GCMP) seniprutug https://lk.regmed.ru/register/EAEU_SmPC

5. Nasonov EL, Mazurov VI, Lila AM, et al. Efficacy and safety of BCD-180, a monoclonal antibody to TRBV9+ T lymphocytes, in patients with active radiological axial spondyloarthritis: results of a 36-week randomized double-blind placebo-controlled phase 2 clinical trial of ELEFTA. Nauchno-prakticheskaya revmatologiya. 2024;62(1):65–80. (In Russ.)